ANGLE (ANPCY) COGS-to-Revenue : 0.38 (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ANGLE COGS-to-Revenue?

ANGLE's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.57 Mil. Its Revenue for the six months ended in Jun. 2023 was $1.51 Mil.

ANGLE's COGS to Revenue for the six months ended in Jun. 2023 was 0.38.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ANGLE's Gross Margin % for the six months ended in Jun. 2023 was 61.99%.

ANGLE COGS-to-Revenue Historical Data

The historical data trend for ANGLE's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANGLE COGS-to-Revenue Chart

ANGLE Annual Data

Trend

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

0.27

0.23

0.22

0.30

0.41

ANGLE Semi-Annual Data
	Oct13	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															0.26	0.31	0.38	0.43	0.38

ANGLE COGS-to-Revenue Calculation

ANGLE's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.521	/	1.268
	=	0.41

ANGLE's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.574	/	1.51
	=	0.38

ANGLE (OTCPK:ANPCY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ANGLE's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.574 / 1.51
	=	61.99 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

ANGLE COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ANGLE's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ANGLE (ANPCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (OTCPK:ANPCY) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ANPCF:USA AGL:UK DWV:Germany

Address

10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF

Website

https://www.angleplc.com

ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.

ANGLE (ANPCY) Headlines

From GuruFocus

Angle PLC Announces Holding(s) in Company - (1)

By ACCESSWIRE ACCESSWIRE • 07-08-2020

Angle PLC Announces Exercise of Options and Total Voting Rights

By ACCESSWIRE ACCESSWIRE • 04-30-2021

Angle PLC Announces Holding(s) in Company - (2)

By ACCESSWIRE ACCESSWIRE • 07-08-2020

Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker

By ACCESSWIRE ACCESSWIRE • 02-18-2021

Angle PLC Announces AACR 2019

By ACCESSWIRE AccessWire • 04-12-2019

Angle PLC Announces Harvesting CTCs from Brain Metastasis Patients

By ACCESSWIRE ACCESSWIRE • 07-09-2021